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The current emphasis on comparative effectiveness re-
search will provide practicing physicians with increasing
volumes of observational evidence about preventive care.
However, numerous highly publicized observational stud-
ies of the effect of prevention on health outcomes have
reported exaggerated relationships that were later contra-
dicted by randomized controlled trials. A growing body of
research has identified sources of bias in observational
studies that are related to patient behaviors or underlying
patient characteristics, known as the healthy user effect,
the healthy adherer effect, confounding by functional
status or cognitive impairment, and confounding by
selective prescribing. In this manuscript we briefly review
observational studies of prevention that have appeared to
reach incorrect conclusions. We then describe potential
sources of bias in these studies and discuss study
designs, analyticalmethods, and sensitivity analyses that
may mitigate bias or increase confidence in the results
reported. More careful consideration of these sources of
bias and study designs by providers can enhance evi-
dence-based decision-making.
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P racticing clinicians face a substantial challenge whenattempting to interpret data from observational studies
that report the effects of prevention on patient health out-
comes. Numerous high-profile descriptive studies of preventive
screening tests, behaviors, and treatments have reported
dramatically reduced mortality or improved health outcomes.
However, many of these findings were later thrown into
question when randomized controlled trials (RCTs) indicated
contradictory results. In some cases, the flawed observational
studies were the source of evidence for broad practice recom-
mendations.1 While it would be a mistake to ignore all evidence
from observational studies—there are many questions that will
never be answered by RCTs—clinicians must be careful when
interpreting observational studies demonstrating what seem to
be surprisingly large beneficial effects of preventive therapy.
With the investment of over $1 billion in comparative
effectiveness research, clinicians will be faced with increasing
volumes of complex results. Proper interpretation will require
familiarity with a host of sources of bias in observational
research. Bias results when features of a study’s design lead to
estimates that do not accurately reflect the relationship
between the study variables. In this review, we explore a
specific subset of these sources of bias—confounding in
observational studies resulting from patient-level tendencies
to engage in healthy behaviors or physician’s perceptions of the
health of patients. A recent body of research has emerged
examining these sources of bias, and their effect on the
interpretation of observational research findings. In this paper,
we provide a brief review of observational studies that have
appeared to reach incorrect conclusions due to healthy user
and other related types of bias. We describe the sources of bias in
these studies and discuss study designs, analytic methods, and
sensitivity analyses thatmaymitigate bias or increase confidence
in the results reported. We offer guidance to physicians to
encourage a more critical review of the literature with the goal of
enhancing evidence-based, rational clinical decision-making.
PRIOR FAILURES OF OBSERVATIONAL RESEARCH
The best known example of a divergence between observational
and RCT evidence is the story of hormone replacement therapy
(HRT) and cardiovascular disease. In 1985, investigators from
the Nurses Health Study reported that post-menopausal
women taking HRT had one third the risk of coronary heart
disease as women not taking HRT.2 A series of observational
studies reporting similar findings followed.1 On this basis,
both the American Heart Association and the American College
of Physicians recommended HRT for prevention of coronary
heart disease in post-menopausal women, and by 2001, an
estimated 15 million women were filling HRT prescriptions
annually.3 The HERS trial, which found no overall cardiovas-
cular benefit of HRT in women with existing coronary disease
and some evidence of early increased risk, was published in
1998.4 The results of Women’s Health Initiative, a more
definitive RCT of HRT in post-menopausal women published
in 2002, reported a 29% increase in the incidence of CHD
among women randomized to HRT.5 While debate continues
about the risks and benefits of HRT for specific subgroups, the
original observational studies seemed to overstate the benefits
of preventive therapy.
Similar stories can be told about a wide array of vitamins
and prescription drugs. Observational studies have suggested
that vitamins B, C, and E, and beta-carotene consumption all
reduce cardiovascular mortality, only to be overturned by
subsequent RCT evidence suggesting no benefit.6–8 The appar-
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ent protective effects of fiber and folic acid intake on the
incidence of colorectal cancer found in observational studies
also were not supported by RCTs.9 Observational studies of
statin use and hip fracture have consistently reported a
protective effect, with a 23% reduction estimated in a recent
meta-analysis.10 However, published secondary analyses of
trial data have not found a protective effect of statins on hip
fracture.10 The reported benefit of statins on Alzheimer’s
disease,11 sepsis,12 and cancer13 have also been questioned.
Another topic of recent debate is the magnitude of the
benefit of influenza vaccination on mortality among elderly
patients. Observational studies have typically reported 40%–
50% reductions in all-cause mortality.14,15 However, the
observation that influenza vaccination appears to protect
patients against mortality prior to the start of the flu season
has cast doubt on these findings,16 as have results indicating
that improved statistical adjustment greatly reduces the
apparent benefit.17
THE HEALTHY USER EFFECT AND RELATED SOURCES
OF BIAS
The deviations in results of observational studies and RCTs
examining the effectiveness of preventive care have fueled a
field of inquiry to seek new sources of bias in observational
research that can explain these deviations and methods to
help adjust for them. In this review, we discuss sources of bias
related to patient health-seeking behavior and physician
perceptions of patient health, an area gaining increased
attention in the literature. We do not perform an exhaustive
review of all sources of bias in observational research.
The healthy user effect. The healthy user effect is best
described as the propensity for patients who receive one
preventive therapy to also seek other preventive services or
partake in other healthy behaviors.18 Patients who choose to
receive preventive therapy may exercise more, eat a
healthier diet, wear a seatbelt when they drive, and avoid
tobacco. As a result, an observational study evaluating the
effect of a preventive therapy (e.g., statin therapy) on a
related outcome (e.g., myocardial infarction) without
adjusting for other related preventive behaviors (e.g.,
healthy diet or exercise) will tend to overstate the effect of
the preventive therapy under study. The healthy user effect
has been widely cited as a likely source of bias in
observational studies of HRT. Studies indicate that women
who took HRT were more likely to engage in healthy
behaviors such as regular exercise, a healthy diet,
abstinence from alcohol, and maintenance of a healthy
weight as compared to non-users.2 The apparent protective
effect of HRT on cardiovascular disease likely reflects these
unmeasured differences in patient characteristics.
The healthy adherer effect. Similarly, the healthy adherer effect
arises when patients who adhere to preventive therapy are
more likely to engage in other healthy behaviors than their
non-adherent counterparts. For example, it has been observed
that patients who adhere to one chronic medication are more
likely to adhere to other therapies22 and more likely to receive
recommended cancer screening tests and immunizations.23,24
In a study of elderly patients initiating statins, patients who
filled two or more statin prescriptions during a 1-year
ascertainment period were more likely than patients who
filled only one prescription to receive prostate-specific antigen
tests [hazard ratio (HR) =1.57, fecal occult blood tests
(HR =1.31), screening mammograms (HR =1.22), influenza
vaccinations (HR =1.21), and pneumococcal vaccinations
(HR =1.46) during follow-up, even after adjusting for
commonly measured covariates.23
This phenomenon can result in biased estimates of the
effect of adherence on clinical outcomes. The most striking
example is the observation that patients adherent to placebo in
RCTs had lower rates of mortality than non-adherent
patients.25,26 A recent study of patients initiating statin
therapy in British Columbia provides another illustration. In
this study, more adherent patients were less likely to have
motor vehicle accidents (hazard ratio, 0.75) and workplace
accidents (hazard ratio, 0.77) than less adherent patients even
after controlling for typical sociodemographic and health
characteristics.24 Failing to account for behaviors that
correlate with medication adherence will lead researchers to
conclude that preventive medication use and adherence to
preventive medications are more strongly associated with
outcomes than is the case.
Confounding by functional status or cognitive impairment.
Cognitive impairment limits some patients’ interest in, or
ability to visit, their physician, and severe functional
impairment may serve as a barrier to travel to a physician’s
office. One study of elderly female patients found that patients
with higher levels of functional impairment, who presumably
are sicker than those without such impairment, also had
significantly lower rates of breast and cervical cancer
screening.27 This type of confounding has been cited as an
explanation for the large observed protective effect of influenza
vaccination on mortality risk. A nested case-control study
found that functional limitations, such as the need for
assistance bathing, were much more common in patients
dying during the flu season than in age-matched controls
and were associated with a decreased probability of receiving
an influenza vaccination. Adjusting for these factors
attenuated the estimated protective effect of flu shots on all-
cause mortality from 41% to 29%.17 Observational studies that
do not account for functional status or cognitive impairment
will overstate the effect of a preventive therapy if sicker
patients disproportionately do not receive preventive therapies.
Confounding by selective prescribing. Physicians frequently
decide not to prescribe preventive therapy to patients who are
frail or who have terminal or acute illness, both in hospitalized
patients and in the outpatient setting.28 One study evaluated
characteristics of patients who received statins and found that
“frail” patients experienced a 26%–33% reduced odds of
receiving lipid-lowering therapy compared to patients who
were not frail and that this relationship could, at least
partially, explain previously documented relationships
between statin use and mortality.29 This is another factor
that has been suggested in explaining the effect of flu shots on
mortality. Several studies have observed that patients who are
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hospitalized during the fall when flu shots are being
administered have low rates of vaccination30,31 and high
rates of mortality.31 Similarly, patients who develop serious
comorbid conditions, such as cancer or end-stage renal
disease, may be more likely to discontinue a preventive
therapy.
EVALUATING STUDY DESIGN AND ADJUSTMENT
METHODS
While no methodology will completely eliminate bias in
observational research, a number of approaches can be used
to minimize bias and affirm the validity of the results. Critical
readers of the observational literature must assess whether
the authors have adequately minimized bias through appro-
priate study design and statistical analysis (Table 1).
Prevalent versus new user designs. Studies comparing
prevalent users of preventive therapy with non-users are
often problematic. In contrast to patients who are new users
of therapy, a prevalent user population is likely to be enriched
with patients who are adherent to and tolerant of the
medication under study. These patients are likely different
from apparently similar non-users, as they have initiated the
preventive therapy and remained adherent to it. For this
reason, “new user” designs, where treatment initiators are
compared to similar non-initiators, are viewed as preferable.
Even with a new user study design, healthy adherer effects
can still bias an as-treated or on-treatment analysis (i.e., an
analysis where patients who discontinue treatment are
censored from the analysis) if non-adherence is potentially
informative. For this reason, an intention-to-treat analysis
(where patients who were once treated are analyzed as always
treated) should be conducted with adjustment for other
potential confounders.
Active comparator. While new user designs can guard against
healthy adherer bias, healthy user bias can still occur. One
way of reducing differences between patients initiating a
preventive therapy and non-initiating comparators is to
select the comparison group from patients who initiated a
different preventive therapy.32 Comparisons between
populations of patients that have all received preventive
therapy will be more interpretable than studies where one
group received no therapy at all, as those comparisons are
more likely to be biased by unmeasured patient
characteristics.
Improved statistical adjustment. Unfortunately, there is no
simple way to control for most biases described here using
typical health care datasets, the source of most epidemiologic
studies of prevention, because many variables of interest are
unmeasured. However, we may able to identify proxies for
many important hypothetical unmeasured confounders. For
example, the use of preventive services such as age- or
condition-specific use of vaccines, mammography, or
colonoscopy may help to control for the healthy user effect.
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adjusting for past adherence to other chronic medications. We
may be able to develop a functional or cognitive capacity score
that incorporates use of medications for dementia as well as
length of stays in nursing homes and rehabilitation centers.
Further predictors of selective prescribing may also be used in
multivariable analyses to more fully control for confounding.
There is an important opportunity for researchers to create
and validate measures that better adjust for confounding in
studies of preventive therapies. New computing-intensive
techniques provide the ability to simultaneously adjust for
hundreds of covariates and may better control for these types
of confounding.33
Sensitivity/secondary analyses. In the absence of better indices
to control for these biases, a number of diagnostic tests can be
used. One approach is to evaluate “negative control outcomes,”
events that should be unaffected by the treatment under study
but may be related to the phenomenon causing bias (e.g.,
healthy user effect). In an unbiased analysis, there would be
no association between the treatment and these control
outcomes. An example of such a design was a recent study
evaluating the effect of flu shot receipt in patients before the flu
season began, which found a strong association between flu
shots and mortality, suggesting that the improved outcomes
were not due to the influenza vaccines themselves.16
Negative control exposures may also be used. In such a
design, the exposure would not be expected to have a biological
effect on the study outcome, but might be influenced by health
status or health-seeking behavior in the same way the study
exposure is. As an example, one study of the effects of statin
and beta-blocker adherence on mortality in post-MI patients
adjusted for adherence to calcium channel blockers (the
negative control exposure). This was included on the grounds
that calcium channel blockers do not have a demonstrated
benefit on mortality post-MI, but the adherence behavior itself
may be related to the outcome.34
Instrumental variable methods or quasi-experimental designs
can also be used to generate unbiased estimates in some
situations.23,35,36 Dose-response relationships can be tested to
better assess the strength of the relationship between the
preventive therapy and the outcome in question. Additionally,
researchers can restrict the study to a population that is likely to
be more homogenous with regard to health-seeking status to
assess if there is a difference in result. A study of the effect of flu
shots restricted the population to those that had an optometry
visit in the past year, dramatically reducing the strength of the
observed relationship between flu shots and mortality.17
ADVICE FOR PRACTICING PHYSICIANS
When interpreting epidemiologic studies of prevention in the
scientific literature, we recommend a healthy skepticism when
encountering what seem like surprising large beneficial effects
of preventive therapies. Readers must first assess the plausi-
bility of results. For example, one argument against the
plausibility of the finding that flu shots reduce mortality by
50% is the observation that the flu season is only associated
with a 10% increase in all-cause mortality.37
It also is important to consider whether the sources of
confounding listed here could potentially result in bias,
and if so whether they were considered in the analysis.
When evaluating observational studies of preventive ser-
vices, clinicians should ask themselves if the service may
have been administered differentially between the study
groups due to baseline health or health-seeking character-
istics of patients. If so, clinicians should conduct a quick
checklist prior to interpreting the results: Did the authors
consider this source of bias? Do the absolute values of the
effect size make sense? Are they clinically meaningful?
Prior to interpreting the results, clinicians should assess
whether the authors conducted sensitivity analyses to
explore the effect of these biases on the results. Did they
look at only new users of a preventive service or all users,
and did they require controls to have used an active
comparator? What types of sensitivity analyses were per-
formed to adjust for these sources of bias? Did the authors
use instrumental variables, consider negative control
exposures or outcomes, or limit the sample to a more
homogeneous subsample as sensitivity analyses, and did
these attenuate the relationships?
Consideration of these sources of potential bias, and
efforts to control for these biases are essential to better
evaluate the credibility of this literature. While randomized
controlled trials are required before bringing new preven-
tive therapies to market, we often rely on observational
data to more fully assess the risks and benefits of
therapies. A more comprehensive approach to reading this
literature will help providers to better assess the quality of
the information being purveyed and should help to deter-
mine how conclusive the results seem to be. Intriguing
findings that have not thoughtfully accounted for these
sources of bias should lead clinicians to call for specific
prospective RCT evidence to enhance clinical decision-making
regarding preventive services. Clinicians should be skeptical
when interpreting results of observational studies of preventive
services that have not accounted for healthy user and related
biases. Such skepticism should enhance a clinicians ability to
prioritize the available evidence and hopefully will improve
clinical decision-making.
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